TransMedics Group, Inc.
General ticker "TMDX" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $3.8B (TTM average)
TransMedics Group, Inc. does not follow the US Stock Market performance with the rate: -26.5%.
Estimated limits based on current volatility of 2.7%: low 73.32$, high 77.46$
Factors to consider:
- Total employees count: 898 (+23.4%) as of 2025
- US accounted for 3.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Customer concentration, Regulatory and compliance, Cybersecurity threats, Labor/talent shortage/retention, Aircraft accident risks
- Current price 20.5% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [89.02$, 157.55$]
- 2026-12-31 to 2027-12-31 estimated range: [91.90$, 161.70$]
Financial Metrics affecting the TMDX estimates:
- Negative: with PPE of 43.9 at the end of fiscal year the price was high
- Positive: 15.80 < Operating profit margin, % of 17.93
- Negative: negative Industry operating cash flow (median)
- Positive: 2.37 < Operating cash flow per share per price, % of 4.54
- Positive: 42.26 < Shareholder equity ratio, % of 44.28 <= 49.86
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
- Negative: 0.07 < Interest expense per share per price, % of 0.32
- Positive: Inventory ratio change, % of -2.16 <= -1.30
- Positive: -2.60 < Investing cash flow per share per price, % of -1.39
Short-term TMDX quotes
Long-term TMDX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $241.62MM | $441.54MM | $605.49MM |
| Operating Expenses | $270.35MM | $404.04MM | $496.91MM |
| Operating Income | $-28.73MM | $37.50MM | $108.58MM |
| Non-Operating Income | $2.06MM | $-1.72MM | $-1.06MM |
| Interest Expense | $10.79MM | $14.41MM | $13.78MM |
| R&D Expense | $63.27MM | $55.97MM | $69.06MM |
| Income(Loss) | $-26.67MM | $35.78MM | $107.52MM |
| Taxes | $-1.64MM | $0.32MM | $-82.77MM |
| Net Income(Loss)* | $-25.03MM | $35.46MM | $190.29MM |
| Stockholders Equity | $137.20MM | $228.60MM | $473.10MM |
| Inventory | $44.23MM | $46.55MM | $48.88MM |
| Assets | $706.05MM | $804.08MM | $1,068.37MM |
| Operating Cash Flow | $-13.03MM | $48.80MM | $192.84MM |
| Capital expenditure | $179.06MM | $129.74MM | $59.25MM |
| Investing Cash Flow | $-193.95MM | $-129.30MM | $-59.25MM |
| Financing Cash Flow | $400.42MM | $22.87MM | $16.86MM |
| Earnings Per Share** | $-0.77 | $1.07 | $5.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.